DDMP lactic-acid-bacteria beverage × Moisture change at weeks 4 and 8

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionSelected intermediate-visit question and original gradeRequired	The selected subclaim is “Moisture change at weeks 4 and 8”, grade C, recording positive intermediate findings and loss of the difference by final week 12. Subclaim score, status and axes are absent. Parent grade D with 28 points is retained as the final week-12 verdict context. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Subclaim score, status and axes are absent and are not filled with parent values. Review of the existing content is incomplete.	Distinction between the original wording and grade for weeks 4 and 8 and the parent final-visit verdict	A preserved proposal for follow-up research that distinguishes the original question's scope at each visit. No new investigation, calculation or trial was performed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionPopulation, recruitment and skin conditionRequired	220 healthy Japanese adults with dry skin were randomized. The original summary does not record intermediate-visit effects in other age groups or skin-disease populations. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Detailed eligibility, age distribution, sex, diagnostic or measurement criteria for skin condition, and baseline environmental conditions are unverified. Review of the existing content is incomplete.	Actual participants' ages, eligibility, dry-skin definition and recruitment conditions	A preserved proposal for follow-up research that compares the same formulation with explicitly defined population criteria. No new investigation, calculation or trial was performed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionIdentity of the study beverageRequired	The intervention was a 65 mL lactic-acid-bacteria beverage containing 2.2 mg DDMP. This study exposure is not recast as evidence for general lactic-acid bacteria or probiotics, other beverages, or all DDMP formulations. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Strains, viability, full ingredients and manufacturing specifications, and correspondence across formulations are unverified. Review of the existing content is incomplete.	DDMP content, beverage formulation, other ingredients and product identity	A preserved proposal for follow-up research that distinguishes formulation effects from attribution to individual ingredients. No new investigation, calculation or trial was performed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionIdentical-beverage control without DDMPRequired	The original record describes a control beverage that lacked only DDMP and was otherwise the same lactic-acid-bacteria beverage. This compares the presence and absence of DDMP within that beverage, not consumption versus non-consumption of a general beverage. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Manufacturing and ingredient matching, taste and appearance, and participants' ability to distinguish the beverages are unverified. Review of the existing content is incomplete.	Actual intervention-control differences and ingredient or contact matching	A preserved proposal for follow-up research that clearly specifies the differences from the control. No new investigation, calculation or trial was performed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionRandom allocation and concealmentRequired	S01 is described as a double-blind randomized identical-beverage placebo-controlled parallel trial. The design label is not treated as verification of the entire allocation procedure. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Sequence generation, concealment, who implemented allocation, and group-specific baseline balance are unverified. Review of the existing content is incomplete.	Sequence generation, allocation concealment and implementation	Proposed follow-up trial disclosing allocation procedures; no new investigation, calculation or trial was performed in this production.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionBlinding and assessorsRequired	The original double-blind label is retained. It is not stated that blinding of stratum-corneum moisture assessors and analysts, or its maintenance, was fully verified. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Who was blinded, blinding success, unblinding timing and assessment conditions are unverified. Review of the existing content is incomplete.	Actual blinding of participants, assessors and analysts and its maintenance	A preserved proposal for follow-up research that specifies assessor blinding and measurement conditions. No new investigation, calculation or trial was performed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence condition12-week exposure and adherenceRequired	The source records 12-week follow-up and analysis of protocol-compliant participants. The 2.2 mg/65 mL specification is retained only as the beverage identity; no new consumption instructions are produced. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Daily frequency, actual cumulative exposure, adherence and reasons for protocol violations are unverified. Review of the existing content is incomplete.	Study exposure, consumption records, group-specific adherence and withdrawal criteria	A preserved proposal for follow-up research that distinguishes exposure from the analysis population. No new investigation, calculation or trial was performed.
8	Unverified	Full text not readStored summary read	N08 · Evidence conditionSkin sites and measurement environmentRequired	The original endpoint is stratum-corneum moisture. The summary is not supplemented with an unsupported assertion that skin sites or measurement conditions remained identical. S01	The information currently needed is unverified in the preserved summary. Measurement sites, left-right or repeated measurements, instruments, temperature and humidity, premeasurement conditions and assessors are unverified. Review of the existing content is incomplete.	Skin sites, instruments, temperature and humidity, acclimatization and measurement conditions at each visit	A preserved proposal for follow-up research that specifies measurement conditions at each visit. No new investigation, calculation or trial was performed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionBaseline, units and definition of changeRequired	Final week-12 values are preserved in a.u., while intermediate visits are described as changes from baseline. Absolute values and changes are not combined as the same outcome. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Group-specific baseline values, the exact change calculation, and intermediate absolute values and standard deviations are unverified. Review of the existing content is incomplete.	Units and calculation definitions for absolute moisture values and changes from baseline	A preserved proposal for follow-up research that reports absolute values and change estimates separately. No new investigation, calculation or trial was performed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionMoisture change at week 4Required	The manuscript records changes from baseline at week 4 of +4.28 versus −2.09, P<0.001. No new between-group difference, ratio or CI is calculated, and this is not recast as a sustained 12-week effect. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Week-4 absolute values, SDs or SEs, 95% CI, visit-specific analysis denominators and the exact model are unverified. Review of the existing content is incomplete.	Week-4 changes by group, comparison and uncertainty	A preserved proposal for follow-up research that distinguishes week-4 changes from final effects. No new investigation, calculation or trial was performed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionMoisture change at week 8Required	The manuscript records changes from baseline at week 8 of +8.47 versus +5.17, P=0.002. No new difference, CI or individual improvement rate is produced. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Week-8 absolute values, SDs or SEs, 95% CI, visit-specific denominators and the exact analysis specification are unverified. Review of the existing content is incomplete.	Week-8 changes by group, comparison and uncertainty	A preserved proposal for follow-up research that distinguishes replication of intermediate changes from persistence at the final visit. No new investigation, calculation or trial was performed.
12	Partly verified	Full text not readStored summary read	N12 · Evidence conditionFinal week-12 absolute moisture valuesRequired	Week-12 values were 29.7±7.67 versus 29.7±6.19 a.u., P=0.985. The final null finding is retained alongside the positive intermediate findings; P is not used as proof of an exactly zero effect or equivalence. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. The 95% CI and the range needed to exclude a clinically meaningful benefit are unverified. Review of the existing content is incomplete.	Absolute values, units and P for the prespecified final primary endpoint	A preserved proposal for follow-up research that adequately reports the final-visit effect and uncertainty. No new investigation, calculation or trial was performed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionFinal week-12 change valuesRequired	Week-12 changes were +8.05±6.85 versus +7.92±5.97, P=0.877. These estimates are distinguished from final absolute values with P=0.985. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. The change estimate's 95% CI and the exact between-group effect and clinical importance are unverified. Review of the existing content is incomplete.	Distinction between final changes from baseline and absolute values	A preserved proposal for follow-up research that reports changes and final absolute values separately. No new investigation, calculation or trial was performed.
14	Partly verified	Full text not readStored summary read	N14 · Evidence conditionWhole-time mixed modelRequired	The original explanation states that the whole-time mixed-model P<0.001 concerns differing patterns across visits. It is not recast as a positive week-12 effect or a sustained benefit at every visit. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Model terms, repeated-measure covariance, interaction or main effects, prespecified plans and individual contrasts are unverified. Review of the existing content is incomplete.	Specification of the whole-trajectory test and individual-visit effects	A preserved proposal for follow-up research that distinguishes the whole trajectory from final and intermediate contrasts. No new investigation, calculation or trial was performed.
15	Partly verified	Full text not readStored summary read	N15 · Evidence conditionPrimary-endpoint and intermediate-result hierarchyRequired	The prespecified primary endpoint is stratum-corneum moisture at final week 12. Positive weeks 4 and 8 are recorded but are not promoted to the primary endpoint or used to replace the final conclusion. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Prespecification of week-4 and week-8 analyses, secondary hierarchy, testing order and analysis changes are unverified. Review of the existing content is incomplete.	Hierarchy of the prespecified final week-12 primary endpoint and intermediate visits	A preserved proposal for follow-up research that explicitly specifies the final and intermediate endpoint hierarchy. No new investigation, calculation or trial was performed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionUnreported CIs and meaningful benefitRequired	The manuscript records that the paper reported no 95% CI and that a meaningful benefit therefore cannot be excluded. No new CI, equivalence margin or response threshold is produced. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Visit-specific CIs, prespecified importance thresholds and effect precision are unverified. Review of the existing content is incomplete.	Exact effects, CIs and importance thresholds	A preserved proposal for follow-up research that specifies CIs and importance thresholds. No new investigation, calculation or trial was performed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence condition220 randomized and 213 in PPSRequired	The original counts of 220 randomized and 213 protocol-compliant participants analyzed are retained. The counts are not added together or treated as confirmation of every visit denominator or a complete ITT analysis. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Group-specific PPS, valid visit-specific denominators, FAS or ITT results and exclusion criteria are unverified. Review of the existing content is incomplete.	Distinction between randomized and analyzed populations and group- or visit-specific denominators	A preserved proposal for follow-up research that reports the full randomized population and PPS results together. No new investigation, calculation or trial was performed.
18	Unverified	Full text not readStored summary read	N18 · Evidence conditionWithdrawal, missing data and analysis exclusionsRequired	The manuscript records that the primary analysis used 213 protocol-compliant participants rather than all 220 randomized. No new exclusion count is calculated or missing-data impact established. S01	The information currently needed is unverified in the preserved summary. Reasons, timing and group patterns of missingness, withdrawal or exclusion, and adjustment or sensitivity results are unverified. Review of the existing content is incomplete.	Reasons for withdrawal, missing data, group-specific effects and handling	A preserved proposal for follow-up research that distinguishes the effects of missingness and nonadherence. No new investigation, calculation or trial was performed.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionWithin-group change and between-group comparisonRequired	Group-specific changes at weeks 4, 8 and 12 and their P values are retained exactly as in the preserved summary. Within-group changes alone are not used to create a placebo-relative difference or a new numerical effect. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Exact between-group contrasts, baseline adjustment, model-specific estimates and whether within-group tests were used are unverified. Review of the existing content is incomplete.	Group correspondence and within- or between-group change estimands	A preserved proposal for follow-up research that clearly reports within- and between-group estimands. No new investigation, calculation or trial was performed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionUMIN identifier and reading of prespecified plansRequired	The preserved registration identifier is UMIN000052867. The UMIN number is retained in its original form, and no claim is made that the external registration has been read. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Registration identity and date, prerecruitment plans, visit hierarchy, changes, and full protocol or SAP text have not been read. Review of the existing content is incomplete.	Actual verification scope for registration, protocol, SAP and change history	A preserved proposal for follow-up research that links prespecified plans with the analyses actually performed. No new investigation, calculation or trial was performed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionMultiple visits, sites and testsRequired	Positive weeks 4 and 8, the final week-12 null finding and the whole-time model are different analyses of the same trial. Multiple P values are not counted as independent replications or overall success. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. The total number of tests, site or visit selection, adjustments and prespecified analysis order are unverified. Review of the existing content is incomplete.	Multiplicity specification for intermediate visits, skin sites and analyses	A preserved proposal for follow-up research that distinguishes multiple-visit findings from the final primary endpoint. No new investigation, calculation or trial was performed.
22	Unverified	Full text not readStored summary read	N22 · Evidence conditionConcurrent skin care, season and lifestyleRequired	The source scope is an identical-beverage control and 12-week follow-up. It is not supplemented with a claim that other skin care, climate, diet or lifestyle conditions were completely identical. S01	The information currently needed is unverified in the preserved summary. Concurrent moisturizing or care, lifestyle, season or environment, concomitant medication and analyses of differences are unverified. Review of the existing content is incomplete.	Group-specific concurrent exposures, lifestyle, seasonal conditions and moisturizer or other care records	A preserved proposal for follow-up research that explicitly specifies concurrent conditions. No new investigation, calculation or trial was performed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionProvision of study and placebo beveragesRequired	The original record states that Nissin York supplied the study and placebo beverages. Product provision is not recast as absence of monetary funding or verification of an independent trial. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Provision agreements, support scope, product-quality or manufacturing records and influence on decisions are unverified. Review of the existing content is incomplete.	Manufacturer product support and scope of provision	A proposed follow-up trial disclosing support roles; no new investigation, calculation or trial was performed.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionEmployee authors and contract organizationRequired	The manuscript's affiliations are retained: T.S., M.T. and S.S. at the Nissin York Development Research Institute, and M.M. at M&I Science. Affiliations alone do not verify all research roles or conflicts of interest. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Specific roles and independence in design, analysis, data management, writing and publication decisions are unverified. Review of the existing content is incomplete.	Author affiliations and roles of the company and contract organization	A preserved proposal for follow-up research that separately discloses company and contract-organization roles. No new investigation, calculation or trial was performed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionPublic funding, writing and publication costsRequired	The original summary states that separate public funding, medical-writing and publication costs were not reported. Nonreporting is not judged to establish an absence of support or all conflicts of interest. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Full original funding, medical-writing, publication-cost and other support or COI disclosures have not been read. Review of the existing content is incomplete.	Item-specific reporting of funding, writing and publication support	A preserved proposal for follow-up research that separately discloses each support category. No new investigation, calculation or trial was performed.
26	Partly verified	Full text not readStored summary read	N26 · Evidence conditionSame trial and intermediate or final resultsRequired	Weeks 4, 8 and 12 in S01 Sato2025 concern one report and the same randomized-population and PPS context. Visits, skin sites, references and related sheets are not added as new independent trials or participants. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Independent replication reports under the same conditions and totals of unique trials or participants are not established. Review of the existing content is incomplete.	Report-to-trial, visit, site and denominator relationships and independent replication	A preserved proposal for follow-up research that independently compares the same final and intermediate outcome specifications. No new investigation, calculation or trial was performed.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionPersistence and other formulations or skin outcomesRequired	The manuscript records that positive findings at weeks 4 and 8 were not maintained at the final visit. These are not extended to other skin functions or diseases, general products or sustained long-term efficacy. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Other skin endpoints, follow-up beyond 12 weeks and direct comparisons in other populations or formulations are unverified. Review of the existing content is incomplete.	Distinction between intermediate changes, sustained effects and other skin or clinical outcomes	A preserved proposal for follow-up research that distinguishes persistence from applicability across formulations and populations. No new investigation, calculation or trial was performed.
28	Partly verified	Full text not readStored summary read	N28 · Harm-information gaps supplementing the efficacy tableOriginal safety record and scopeSupplementary	The original parent safety label is Good, and the manuscript records no reported serious safety signal attributed to the study beverage over 12 weeks. This is not recast as absence of all harms or verification of safety for other products or durations. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Adverse-event types, collection and adjudication, group-specific denominators and frequencies, discontinuation, and rare or long-term harms are unverified. Review of the existing content is incomplete.	12-week safety collection, denominators and frequencies, and rare or long-term harms	A preserved proposal for follow-up research that specifies harm collection and the scope of longer-term or other-population evidence. No new investigation, calculation or trial was performed.
29	Partly verified	Full text not readStored summary read	N29 · Evidence conditionParent/subclaim, bilingual text and historyRequired	Parent D28, B/S/R1/I0/E0/B1/C0, three false flags and blank override reasons are retained alongside the selected subclaim's grade C and note. Korean and English texts, 2026-08-26, empty correction and deliberation records, and historical cross-checking are not a current review or a subclaim score. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Subclaim score, status and axes are absent from the source. No new score, axes or completed review are created. Review of the existing content is incomplete.	Separate preservation of original values, axes, reference date and correction or verification statements	A preserved proposal for follow-up research that distinguishes original values and history from application of new updates. No new investigation, calculation or trial was performed.
30	Partly verified	Full text not readStored summary read	N30 · Evidence conditionSummary reading, external materials and linksRequired	The complete preserved summary and references were used for production, and source links are retained. Original articles, registration, protocol, SAP and support or COI materials have not been read or accessed. No separate external-link test was performed. S01	Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. The content and actual accessibility of external original articles, plans and COI materials are unverified. Review of the existing content is incomplete.	Actual reading scope and access status of original articles, registration, plans and support records	A preserved proposal for follow-up research that distinguishes the timing and scope of acquired material when updating. No new investigation, calculation or trial was performed.

No items match your search or filter.

30 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: 220 healthy Japanese adults with dry skin were randomized, and 213 protocol-compliant participants were analyzed. Group- and visit-specific denominators, withdrawals and exclusions, eligibility, measurement sites and conditions are unverified.
Ingredient, formulation and route: The study formulation was a 65 mL lactic-acid-bacteria beverage containing 2.2 mg DDMP. Its full ingredients, strains and viability, product and batch identity, and manufacturing specifications are unverified. The findings are not transferred to general probiotics, other beverages or separate DDMP formulations.
Dose: Only the original study identity of 2.2 mg DDMP in a 65 mL beverage and 12-week follow-up is retained. Actual daily frequency, cumulative exposure and adherence are unverified. No new consumption or care instructions or conversions are produced.
Comparator: An otherwise identical lactic-acid-bacteria beverage without DDMP. The original description of a double-blind randomized parallel comparison is retained. Ingredient and sensory matching, allocation and blinding procedures, and concurrent skin care are unverified.
Measured outcome: Intermediate changes from baseline were +4.28 versus −2.09 at week 4 (P<0.001) and +8.47 versus +5.17 at week 8 (P=0.002). These are distinguished from final week-12 absolute values of 29.7±7.67 versus 29.7±6.19 a.u. (P=0.985) and changes of +8.05±6.85 versus +7.92±5.97 (P=0.877). The whole-time mixed-model P<0.001 concerns a trajectory difference, not a benefit at week 12. No new differences, CIs, effects or grades are calculated.
Duration: Intermediate changes at weeks 4 and 8 and the prespecified final week-12 primary endpoint. Persistence beyond 12 weeks, other skin or clinical outcomes, and effects in other populations or products are unverified.
Questions outside this scope: Calculating new between-group differences, ratios, CIs or response rates from +4.28 versus −2.09 at week 4 or +8.47 versus +5.17 at week 8; Recasting positive intermediate visits or a whole-time mixed-model P<0.001 as prespecified final week-12 efficacy or sustained benefit; Combining final absolute values with changes from baseline, skin sites or measurement conditions, or visit-specific denominators; Treating P=0.985 or P=0.877 as proof of a zero effect, equivalence or exclusion of meaningful benefit; Adding the 220 randomized and 213 analyzed participants, groups, visits, skin sites, references or related sheets as new independent trials or participants; Transferring the DDMP-versus-no-DDMP comparison within the same beverage to all DDMP formulations, probiotics or general beverages, or other skin or clinical effects; Inheriting parent values/axes and historical cross-checks as subclaim scores, current review or original-source reading; New calculations, hypothetical values, effects/CIs, grades, independence certification, drink/extract/product intake, skin/sleep management or treatment-substitution instructions

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Sato T et al. 2025

PubMed

Material type: Double-blind randomized identical-beverage placebo-controlled parallel trial
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: 29.7±7.67 versus 29.7±6.19 a.u., P=0.985; change +8.05±6.85 versus +7.92±5.97, P=0.877; 95% CI not reported. Changes from baseline were positive at week 4, +4.28 versus −2.09 (P<0.001), and week 8, +8.47 versus +5.17 (P=0.002). The difference disappeared by week 12, +8.05 versus +7.92 (P=0.877). A whole-time mixed-model P<0.001 describes different patterns across visits, not a positive week-12 effect.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 Sato2025 is one parallel-trial report involving 220 healthy Japanese adults with dry skin randomized and 213 protocol-compliant participants analyzed. It compared a 65 mL beverage containing 2.2 mg DDMP with an otherwise identical beverage without DDMP for 12 weeks. Changes from baseline at week 4 (+4.28 versus −2.09, P<0.001) and week 8 (+8.47 versus +5.17, P=0.002) are distinguished from final week-12 absolute values (29.7±7.67 versus 29.7±6.19 a.u., P=0.985), changes (+8.05±6.85 versus +7.92±5.97, P=0.877), and the whole-time mixed-model P<0.001. Positive intermediate findings neither replace the prespecified final primary endpoint nor establish sustained benefit. The same groups, visits, skin sites, denominators, references and related sheets are not new independent trials or participants. Report entries are not totals of unique clinical trials, participants or independent replications; no new totals or independence certification are produced.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only stored-summary and bibliographic content was used for production. External material verification/review is not complete.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 Sato2025 is one parallel-trial report involving 220 healthy Japanese adults with dry skin randomized and 213 protocol-compliant participants analyzed. It compared a 65 mL beverage containing 2.2 mg DDMP with an otherwise identical beverage without DDMP for 12 weeks. Changes from baseline at week 4 (+4.28 versus −2.09, P<0.001) and week 8 (+8.47 versus +5.17, P=0.002) are distinguished from final week-12 absolute values (29.7±7.67 versus 29.7±6.19 a.u., P=0.985), changes (+8.05±6.85 versus +7.92±5.97, P=0.877), and the whole-time mixed-model P<0.001. Positive intermediate findings neither replace the prespecified final primary endpoint nor establish sustained benefit. The same groups, visits, skin sites, denominators, references and related sheets are not new independent trials or participants. Report entries are not totals of unique clinical trials, participants or independent replications; no new totals or independence certification are produced.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Selected intermediate-visit question and original grade

Required materials and conditions: Distinction between the original wording and grade for weeks 4 and 8 and the parent final-visit verdict
Conditions for verification: Relevant source data and analysis details for distinction between the original wording and grade for weeks 4 and 8 and the parent final-visit verdict must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes distinction between the original wording and grade for weeks 4 and 8 and the parent final-visit verdict to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

N02 · Population, recruitment and skin condition

Required materials and conditions: Actual participants' ages, eligibility, dry-skin definition and recruitment conditions
Conditions for verification: Relevant source data and analysis details for actual participants' ages, eligibility, dry-skin definition and recruitment conditions must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes actual participants' ages, eligibility, dry-skin definition and recruitment conditions to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.1; Detailed population conditions are Chamgap design; M03 §3.2.1–3.2.4; Dose, duration and effect-modifier details are Chamgap design

N03 · Identity of the study beverage

Required materials and conditions: DDMP content, beverage formulation, other ingredients and product identity
Conditions for verification: Relevant source data and analysis details for DDMP content, beverage formulation, other ingredients and product identity must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes DDMP content, beverage formulation, other ingredients and product identity to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

N04 · Identical-beverage control without DDMP

Required materials and conditions: Actual intervention-control differences and ingredient or contact matching
Conditions for verification: Relevant source data and analysis details for actual intervention-control differences and ingredient or contact matching must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes actual intervention-control differences and ingredient or contact matching to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application

N05 · Random allocation and concealment

Required materials and conditions: Sequence generation, allocation concealment and implementation
Conditions for verification: Relevant source data and analysis details for sequence generation, allocation concealment and implementation must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes sequence generation, allocation concealment and implementation to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 §8.1–8.2.3; Internal application; M03 §3.2.1; Detailed population conditions are internally designed

N06 · Blinding and assessors

Required materials and conditions: Actual blinding of participants, assessors and analysts and its maintenance
Conditions for verification: Relevant source data and analysis details for actual blinding of participants, assessors and analysts and its maintenance must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes actual blinding of participants, assessors and analysts and its maintenance to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; own application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific result adaptation is our own design

N07 · 12-week exposure and adherence

Required materials and conditions: Study exposure, consumption records, group-specific adherence and withdrawal criteria
Conditions for verification: Relevant source data and analysis details for study exposure, consumption records, group-specific adherence and withdrawal criteria must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes study exposure, consumption records, group-specific adherence and withdrawal criteria to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; our own application; M08 §8.2.2, M15 §15.3.1; our own application

N08 · Skin sites and measurement environment

Required materials and conditions: Skin sites, instruments, temperature and humidity, acclimatization and measurement conditions at each visit
Conditions for verification: Relevant source data and analysis details for skin sites, instruments, temperature and humidity, acclimatization and measurement conditions at each visit must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes skin sites, instruments, temperature and humidity, acclimatization and measurement conditions at each visit to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; our own application

N09 · Baseline, units and definition of change

Required materials and conditions: Units and calculation definitions for absolute moisture values and changes from baseline
Conditions for verification: Relevant source data and analysis details for units and calculation definitions for absolute moisture values and changes from baseline must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes units and calculation definitions for absolute moisture values and changes from baseline to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 §8.2.2, M15 §15.3.1; our own application

N10 · Moisture change at week 4

Required materials and conditions: Week-4 changes by group, comparison and uncertainty
Conditions for verification: Relevant source data and analysis details for week-4 changes by group, comparison and uncertainty must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes week-4 changes by group, comparison and uncertainty to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is internally designed; M15 §15.3.1–15.3.3; internal application

N11 · Moisture change at week 8

Required materials and conditions: Week-8 changes by group, comparison and uncertainty
Conditions for verification: Relevant source data and analysis details for week-8 changes by group, comparison and uncertainty must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes week-8 changes by group, comparison and uncertainty to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is internally designed; M15 §15.3.1–15.3.3; internal application

N12 · Final week-12 absolute moisture values

Required materials and conditions: Absolute values, units and P for the prespecified final primary endpoint
Conditions for verification: Relevant source data and analysis details for absolute values, units and P for the prespecified final primary endpoint must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes absolute values, units and P for the prespecified final primary endpoint to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M04 §4.6.3 and M15 §15.3.1–15.3.3: status separation is in-house; M15 §15.3.1–15.3.3: in-house application.

N13 · Final week-12 change values

Required materials and conditions: Distinction between final changes from baseline and absolute values
Conditions for verification: Relevant source data and analysis details for distinction between final changes from baseline and absolute values must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes distinction between final changes from baseline and absolute values to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application

N14 · Whole-time mixed model

Required materials and conditions: Specification of the whole-trajectory test and individual-visit effects
Conditions for verification: Relevant source data and analysis details for specification of the whole-trajectory test and individual-visit effects must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes specification of the whole-trajectory test and individual-visit effects to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 §8.2.2, M15 §15.3.1; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed

N15 · Primary-endpoint and intermediate-result hierarchy

Required materials and conditions: Hierarchy of the prespecified final week-12 primary endpoint and intermediate visits
Conditions for verification: Relevant source data and analysis details for hierarchy of the prespecified final week-12 primary endpoint and intermediate visits must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes hierarchy of the prespecified final week-12 primary endpoint and intermediate visits to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap application; M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap's own design

N16 · Unreported CIs and meaningful benefit

Required materials and conditions: Exact effects, CIs and importance thresholds
Conditions for verification: Relevant source data and analysis details for exact effects, CIs and importance thresholds must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes exact effects, CIs and importance thresholds to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is internally designed; M15 §15.3.1–15.3.3; internal application

N17 · 220 randomized and 213 in PPS

Required materials and conditions: Distinction between randomized and analyzed populations and group- or visit-specific denominators
Conditions for verification: Relevant source data and analysis details for distinction between randomized and analyzed populations and group- or visit-specific denominators must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes distinction between randomized and analyzed populations and group- or visit-specific denominators to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M08 §8.1–8.2.3; internal application

N18 · Withdrawal, missing data and analysis exclusions

Required materials and conditions: Reasons for withdrawal, missing data, group-specific effects and handling
Conditions for verification: Relevant source data and analysis details for reasons for withdrawal, missing data, group-specific effects and handling must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes reasons for withdrawal, missing data, group-specific effects and handling to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N19 · Within-group change and between-group comparison

Required materials and conditions: Group correspondence and within- or between-group change estimands
Conditions for verification: Relevant source data and analysis details for group correspondence and within- or between-group change estimands must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes group correspondence and within- or between-group change estimands to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design

N20 · UMIN identifier and reading of prespecified plans

Required materials and conditions: Actual verification scope for registration, protocol, SAP and change history
Conditions for verification: Relevant source data and analysis details for actual verification scope for registration, protocol, SAP and change history must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes actual verification scope for registration, protocol, SAP and change history to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: Data collection and selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed; M08 Table 8.2.a, M04 §4.6.3; internal application; M04 §4.5, §4.6.3; limits of this material conversion reflect the review scope and internal design

N21 · Multiple visits, sites and tests

Required materials and conditions: Multiplicity specification for intermediate visits, skin sites and analyses
Conditions for verification: Relevant source data and analysis details for multiplicity specification for intermediate visits, skin sites and analyses must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes multiplicity specification for intermediate visits, skin sites and analyses to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort and outcome linkage is an internal application; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed

N22 · Concurrent skin care, season and lifestyle

Required materials and conditions: Group-specific concurrent exposures, lifestyle, seasonal conditions and moisturizer or other care records
Conditions for verification: Relevant source data and analysis details for group-specific concurrent exposures, lifestyle, seasonal conditions and moisturizer or other care records must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes group-specific concurrent exposures, lifestyle, seasonal conditions and moisturizer or other care records to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; own application; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design

N23 · Provision of study and placebo beverages

Required materials and conditions: Manufacturer product support and scope of provision
Conditions for verification: Relevant source data and analysis details for manufacturer product support and scope of provision must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes manufacturer product support and scope of provision to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N24 · Employee authors and contract organization

Required materials and conditions: Author affiliations and roles of the company and contract organization
Conditions for verification: Relevant source data and analysis details for author affiliations and roles of the company and contract organization must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes author affiliations and roles of the company and contract organization to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N25 · Public funding, writing and publication costs

Required materials and conditions: Item-specific reporting of funding, writing and publication support
Conditions for verification: Relevant source data and analysis details for item-specific reporting of funding, writing and publication support must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes item-specific reporting of funding, writing and publication support to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

N26 · Same trial and intermediate or final results

Required materials and conditions: Report-to-trial, visit, site and denominator relationships and independent replication
Conditions for verification: Relevant source data and analysis details for report-to-trial, visit, site and denominator relationships and independent replication must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes report-to-trial, visit, site and denominator relationships and independent replication to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N27 · Persistence and other formulations or skin outcomes

Required materials and conditions: Distinction between intermediate changes, sustained effects and other skin or clinical outcomes
Conditions for verification: Relevant source data and analysis details for distinction between intermediate changes, sustained effects and other skin or clinical outcomes must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes distinction between intermediate changes, sustained effects and other skin or clinical outcomes to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed; M03 §3.2.4; internally defined extension boundaries; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed

N28 · Original safety record and scope

Required materials and conditions: 12-week safety collection, denominators and frequencies, and rare or long-term harms
Conditions for verification: Relevant source data and analysis details for 12-week safety collection, denominators and frequencies, and rare or long-term harms must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Supplementary
Application exceptions: Complements safety-data gaps for the selected subclaim. Intermediate/final skin hydration, self-reported sleepiness or parent cautionary wording are not used to judge safety or create harm-incidence estimates/new use instructions.
Why this condition is needed: This item distinguishes 12-week safety collection, denominators and frequencies, and rare or long-term harms to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are Chamgap’s own design; M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Chamgap application

N29 · Parent/subclaim, bilingual text and history

Required materials and conditions: Separate preservation of original values, axes, reference date and correction or verification statements
Conditions for verification: Relevant source data and analysis details for separate preservation of original values, axes, reference date and correction or verification statements must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes separate preservation of original values, axes, reference date and correction or verification statements to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

N30 · Summary reading, external materials and links

Required materials and conditions: Actual reading scope and access status of original articles, registration, plans and support records
Conditions for verification: Relevant source data and analysis details for actual reading scope and access status of original articles, registration, plans and support records must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: This item distinguishes actual reading scope and access status of original articles, registration, plans and support records to connect the evidence needed for the selected question with the evidence currently available.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: Existing content review remains incomplete.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-14 · Public page/material version 1.0

The public page and data were prepared from the existing 30 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Selected intermediate-visit question and original grade

Current findings: The selected subclaim is “Moisture change at weeks 4 and 8”, grade C, recording positive intermediate findings and loss of the difference by final week 12. Subclaim score, status and axes are absent. Parent grade D with 28 points is retained as the final week-12 verdict context.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Subclaim score, status and axes are absent and are not filled with parent values. Review of the existing content is incomplete.
Reason for missing information: Subclaim score, status and axes are absent and are not filled with parent values.
Required materials and conditions: Distinction between the original wording and grade for weeks 4 and 8 and the parent final-visit verdict
Materials to obtain first: Original selected question and parent verdict, and user corrections
Further research: A preserved proposal for follow-up research that distinguishes the original question's scope at each visit. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for distinction between the original wording and grade for weeks 4 and 8 and the parent final-visit verdict must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes distinction between the original wording and grade for weeks 4 and 8 and the parent final-visit verdict to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design

Related sources S01

N02 · Population, recruitment and skin condition

Current findings: 220 healthy Japanese adults with dry skin were randomized. The original summary does not record intermediate-visit effects in other age groups or skin-disease populations.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Detailed eligibility, age distribution, sex, diagnostic or measurement criteria for skin condition, and baseline environmental conditions are unverified. Review of the existing content is incomplete.
Reason for missing information: Detailed eligibility, age distribution, sex, diagnostic or measurement criteria for skin condition, and baseline environmental conditions are unverified.
Required materials and conditions: Actual participants' ages, eligibility, dry-skin definition and recruitment conditions
Materials to obtain first: Eligibility, recruitment and baseline-characteristic tables
Further research: A preserved proposal for follow-up research that compares the same formulation with explicitly defined population criteria. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for actual participants' ages, eligibility, dry-skin definition and recruitment conditions must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes actual participants' ages, eligibility, dry-skin definition and recruitment conditions to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; Detailed population conditions are Chamgap design; M03 §3.2.1–3.2.4; Dose, duration and effect-modifier details are Chamgap design

Related sources S01

N03 · Identity of the study beverage

Current findings: The intervention was a 65 mL lactic-acid-bacteria beverage containing 2.2 mg DDMP. This study exposure is not recast as evidence for general lactic-acid bacteria or probiotics, other beverages, or all DDMP formulations.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Strains, viability, full ingredients and manufacturing specifications, and correspondence across formulations are unverified. Review of the existing content is incomplete.
Reason for missing information: Strains, viability, full ingredients and manufacturing specifications, and correspondence across formulations are unverified.
Required materials and conditions: DDMP content, beverage formulation, other ingredients and product identity
Materials to obtain first: Ingredient, manufacturing and identity records for the study and control beverages
Further research: A preserved proposal for follow-up research that distinguishes formulation effects from attribution to individual ingredients. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for DDMP content, beverage formulation, other ingredients and product identity must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes DDMP content, beverage formulation, other ingredients and product identity to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

Related sources S01

N04 · Identical-beverage control without DDMP

Current findings: The original record describes a control beverage that lacked only DDMP and was otherwise the same lactic-acid-bacteria beverage. This compares the presence and absence of DDMP within that beverage, not consumption versus non-consumption of a general beverage.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Manufacturing and ingredient matching, taste and appearance, and participants' ability to distinguish the beverages are unverified. Review of the existing content is incomplete.
Reason for missing information: Manufacturing and ingredient matching, taste and appearance, and participants' ability to distinguish the beverages are unverified.
Required materials and conditions: Actual intervention-control differences and ingredient or contact matching
Materials to obtain first: Control ingredient, sensory and manufacturing matching records
Further research: A preserved proposal for follow-up research that clearly specifies the differences from the control. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for actual intervention-control differences and ingredient or contact matching must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes actual intervention-control differences and ingredient or contact matching to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application

Related sources S01

N05 · Random allocation and concealment

Current findings: S01 is described as a double-blind randomized identical-beverage placebo-controlled parallel trial. The design label is not treated as verification of the entire allocation procedure.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Sequence generation, concealment, who implemented allocation, and group-specific baseline balance are unverified. Review of the existing content is incomplete.
Reason for missing information: Sequence generation, concealment, who implemented allocation, and group-specific baseline balance are unverified.
Required materials and conditions: Sequence generation, allocation concealment and implementation
Materials to obtain first: Randomization, allocation-concealment and baseline tables
Further research: Proposed follow-up trial disclosing allocation procedures; no new investigation, calculation or trial was performed in this production.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for sequence generation, allocation concealment and implementation must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes sequence generation, allocation concealment and implementation to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.1–8.2.3; Internal application; M03 §3.2.1; Detailed population conditions are internally designed

Related sources S01

N06 · Blinding and assessors

Current findings: The original double-blind label is retained. It is not stated that blinding of stratum-corneum moisture assessors and analysts, or its maintenance, was fully verified.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Who was blinded, blinding success, unblinding timing and assessment conditions are unverified. Review of the existing content is incomplete.
Reason for missing information: Who was blinded, blinding success, unblinding timing and assessment conditions are unverified.
Required materials and conditions: Actual blinding of participants, assessors and analysts and its maintenance
Materials to obtain first: Blinding procedures and assessor-role records
Further research: A preserved proposal for follow-up research that specifies assessor blinding and measurement conditions. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for actual blinding of participants, assessors and analysts and its maintenance must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes actual blinding of participants, assessors and analysts and its maintenance to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M03 §3.2.4; own application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific result adaptation is our own design

Related sources S01

N07 · 12-week exposure and adherence

Current findings: The source records 12-week follow-up and analysis of protocol-compliant participants. The 2.2 mg/65 mL specification is retained only as the beverage identity; no new consumption instructions are produced.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Daily frequency, actual cumulative exposure, adherence and reasons for protocol violations are unverified. Review of the existing content is incomplete.
Reason for missing information: Daily frequency, actual cumulative exposure, adherence and reasons for protocol violations are unverified.
Required materials and conditions: Study exposure, consumption records, group-specific adherence and withdrawal criteria
Materials to obtain first: Exposure, adherence and protocol-compliance criteria
Further research: A preserved proposal for follow-up research that distinguishes exposure from the analysis population. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for study exposure, consumption records, group-specific adherence and withdrawal criteria must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes study exposure, consumption records, group-specific adherence and withdrawal criteria to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; our own application; M08 §8.2.2, M15 §15.3.1; our own application

Related sources S01

N08 · Skin sites and measurement environment

Current findings: The original endpoint is stratum-corneum moisture. The summary is not supplemented with an unsupported assertion that skin sites or measurement conditions remained identical.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: The information currently needed is unverified in the preserved summary. Measurement sites, left-right or repeated measurements, instruments, temperature and humidity, premeasurement conditions and assessors are unverified. Review of the existing content is incomplete.
Reason for missing information: Measurement sites, left-right or repeated measurements, instruments, temperature and humidity, premeasurement conditions and assessors are unverified.
Required materials and conditions: Skin sites, instruments, temperature and humidity, acclimatization and measurement conditions at each visit
Materials to obtain first: Measurement manuals and site- or environment-specific results
Further research: A preserved proposal for follow-up research that specifies measurement conditions at each visit. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for skin sites, instruments, temperature and humidity, acclimatization and measurement conditions at each visit must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes skin sites, instruments, temperature and humidity, acclimatization and measurement conditions at each visit to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; our own application

Related sources S01

N09 · Baseline, units and definition of change

Current findings: Final week-12 values are preserved in a.u., while intermediate visits are described as changes from baseline. Absolute values and changes are not combined as the same outcome.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Group-specific baseline values, the exact change calculation, and intermediate absolute values and standard deviations are unverified. Review of the existing content is incomplete.
Reason for missing information: Group-specific baseline values, the exact change calculation, and intermediate absolute values and standard deviations are unverified.
Required materials and conditions: Units and calculation definitions for absolute moisture values and changes from baseline
Materials to obtain first: Baseline and visit-specific absolute-value or change tables and analysis definitions
Further research: A preserved proposal for follow-up research that reports absolute values and change estimates separately. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for units and calculation definitions for absolute moisture values and changes from baseline must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes units and calculation definitions for absolute moisture values and changes from baseline to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 §8.2.2, M15 §15.3.1; our own application

Related sources S01

N10 · Moisture change at week 4

Current findings: The manuscript records changes from baseline at week 4 of +4.28 versus −2.09, P<0.001. No new between-group difference, ratio or CI is calculated, and this is not recast as a sustained 12-week effect.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Week-4 absolute values, SDs or SEs, 95% CI, visit-specific analysis denominators and the exact model are unverified. Review of the existing content is incomplete.
Reason for missing information: Week-4 absolute values, SDs or SEs, 95% CI, visit-specific analysis denominators and the exact model are unverified.
Required materials and conditions: Week-4 changes by group, comparison and uncertainty
Materials to obtain first: Week-4 results, denominators, analysis and CI records
Further research: A preserved proposal for follow-up research that distinguishes week-4 changes from final effects. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for week-4 changes by group, comparison and uncertainty must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes week-4 changes by group, comparison and uncertainty to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is internally designed; M15 §15.3.1–15.3.3; internal application

Related sources S01

N11 · Moisture change at week 8

Current findings: The manuscript records changes from baseline at week 8 of +8.47 versus +5.17, P=0.002. No new difference, CI or individual improvement rate is produced.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Week-8 absolute values, SDs or SEs, 95% CI, visit-specific denominators and the exact analysis specification are unverified. Review of the existing content is incomplete.
Reason for missing information: Week-8 absolute values, SDs or SEs, 95% CI, visit-specific denominators and the exact analysis specification are unverified.
Required materials and conditions: Week-8 changes by group, comparison and uncertainty
Materials to obtain first: Week-8 results, denominators, analysis and CI records
Further research: A preserved proposal for follow-up research that distinguishes replication of intermediate changes from persistence at the final visit. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for week-8 changes by group, comparison and uncertainty must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes week-8 changes by group, comparison and uncertainty to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is internally designed; M15 §15.3.1–15.3.3; internal application

Related sources S01

N12 · Final week-12 absolute moisture values

Current findings: Week-12 values were 29.7±7.67 versus 29.7±6.19 a.u., P=0.985. The final null finding is retained alongside the positive intermediate findings; P is not used as proof of an exactly zero effect or equivalence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. The 95% CI and the range needed to exclude a clinically meaningful benefit are unverified. Review of the existing content is incomplete.
Reason for missing information: The 95% CI and the range needed to exclude a clinically meaningful benefit are unverified.
Required materials and conditions: Absolute values, units and P for the prespecified final primary endpoint
Materials to obtain first: Final absolute-value estimates, CIs and analysis tables
Further research: A preserved proposal for follow-up research that adequately reports the final-visit effect and uncertainty. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for absolute values, units and P for the prespecified final primary endpoint must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes absolute values, units and P for the prespecified final primary endpoint to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3: question-specific outcome adaptation is in-house; M04 §4.6.3 and M15 §15.3.1–15.3.3: status separation is in-house; M15 §15.3.1–15.3.3: in-house application.

Related sources S01

N13 · Final week-12 change values

Current findings: Week-12 changes were +8.05±6.85 versus +7.92±5.97, P=0.877. These estimates are distinguished from final absolute values with P=0.985.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. The change estimate's 95% CI and the exact between-group effect and clinical importance are unverified. Review of the existing content is incomplete.
Reason for missing information: The change estimate's 95% CI and the exact between-group effect and clinical importance are unverified.
Required materials and conditions: Distinction between final changes from baseline and absolute values
Materials to obtain first: Baseline adjustment, change estimates and CIs
Further research: A preserved proposal for follow-up research that reports changes and final absolute values separately. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for distinction between final changes from baseline and absolute values must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes distinction between final changes from baseline and absolute values to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M15 §15.3.1–15.3.3; internal application

Related sources S01

N14 · Whole-time mixed model

Current findings: The original explanation states that the whole-time mixed-model P<0.001 concerns differing patterns across visits. It is not recast as a positive week-12 effect or a sustained benefit at every visit.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Model terms, repeated-measure covariance, interaction or main effects, prespecified plans and individual contrasts are unverified. Review of the existing content is incomplete.
Reason for missing information: Model terms, repeated-measure covariance, interaction or main effects, prespecified plans and individual contrasts are unverified.
Required materials and conditions: Specification of the whole-trajectory test and individual-visit effects
Materials to obtain first: Mixed-model and repeated-measure plans and results, and visit-specific contrasts
Further research: A preserved proposal for follow-up research that distinguishes the whole trajectory from final and intermediate contrasts. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for specification of the whole-trajectory test and individual-visit effects must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes specification of the whole-trajectory test and individual-visit effects to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2, M15 §15.3.1; internal application; M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed

Related sources S01

N15 · Primary-endpoint and intermediate-result hierarchy

Current findings: The prespecified primary endpoint is stratum-corneum moisture at final week 12. Positive weeks 4 and 8 are recorded but are not promoted to the primary endpoint or used to replace the final conclusion.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Prespecification of week-4 and week-8 analyses, secondary hierarchy, testing order and analysis changes are unverified. Review of the existing content is incomplete.
Reason for missing information: Prespecification of week-4 and week-8 analyses, secondary hierarchy, testing order and analysis changes are unverified.
Required materials and conditions: Hierarchy of the prespecified final week-12 primary endpoint and intermediate visits
Materials to obtain first: Visit and hierarchy records in the registration, protocol and SAP
Further research: A preserved proposal for follow-up research that explicitly specifies the final and intermediate endpoint hierarchy. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for hierarchy of the prespecified final week-12 primary endpoint and intermediate visits must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes hierarchy of the prespecified final week-12 primary endpoint and intermediate visits to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap application; M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is Chamgap's own design

Related sources S01

N16 · Unreported CIs and meaningful benefit

Current findings: The manuscript records that the paper reported no 95% CI and that a meaningful benefit therefore cannot be excluded. No new CI, equivalence margin or response threshold is produced.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Visit-specific CIs, prespecified importance thresholds and effect precision are unverified. Review of the existing content is incomplete.
Reason for missing information: Visit-specific CIs, prespecified importance thresholds and effect precision are unverified.
Required materials and conditions: Exact effects, CIs and importance thresholds
Materials to obtain first: Original result tables, CIs and prespecified importance thresholds
Further research: A preserved proposal for follow-up research that specifies CIs and importance thresholds. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for exact effects, CIs and importance thresholds must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes exact effects, CIs and importance thresholds to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is internally designed; M15 §15.3.1–15.3.3; internal application

Related sources S01

N17 · 220 randomized and 213 in PPS

Current findings: The original counts of 220 randomized and 213 protocol-compliant participants analyzed are retained. The counts are not added together or treated as confirmation of every visit denominator or a complete ITT analysis.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Group-specific PPS, valid visit-specific denominators, FAS or ITT results and exclusion criteria are unverified. Review of the existing content is incomplete.
Reason for missing information: Group-specific PPS, valid visit-specific denominators, FAS or ITT results and exclusion criteria are unverified.
Required materials and conditions: Distinction between randomized and analyzed populations and group- or visit-specific denominators
Materials to obtain first: Participant flow, analysis-population and visit-specific denominator tables
Further research: A preserved proposal for follow-up research that reports the full randomized population and PPS results together. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for distinction between randomized and analyzed populations and group- or visit-specific denominators must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes distinction between randomized and analyzed populations and group- or visit-specific denominators to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M08 §8.1–8.2.3; internal application

Related sources S01

N18 · Withdrawal, missing data and analysis exclusions

Current findings: The manuscript records that the primary analysis used 213 protocol-compliant participants rather than all 220 randomized. No new exclusion count is calculated or missing-data impact established.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: The information currently needed is unverified in the preserved summary. Reasons, timing and group patterns of missingness, withdrawal or exclusion, and adjustment or sensitivity results are unverified. Review of the existing content is incomplete.
Reason for missing information: Reasons, timing and group patterns of missingness, withdrawal or exclusion, and adjustment or sensitivity results are unverified.
Required materials and conditions: Reasons for withdrawal, missing data, group-specific effects and handling
Materials to obtain first: Participant-flow diagrams, missing-data handling and sensitivity results
Further research: A preserved proposal for follow-up research that distinguishes the effects of missingness and nonadherence. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for reasons for withdrawal, missing data, group-specific effects and handling must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes reasons for withdrawal, missing data, group-specific effects and handling to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources S01

N19 · Within-group change and between-group comparison

Current findings: Group-specific changes at weeks 4, 8 and 12 and their P values are retained exactly as in the preserved summary. Within-group changes alone are not used to create a placebo-relative difference or a new numerical effect.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Exact between-group contrasts, baseline adjustment, model-specific estimates and whether within-group tests were used are unverified. Review of the existing content is incomplete.
Reason for missing information: Exact between-group contrasts, baseline adjustment, model-specific estimates and whether within-group tests were used are unverified.
Required materials and conditions: Group correspondence and within- or between-group change estimands
Materials to obtain first: Original result tables, group correspondence and contrast definitions
Further research: A preserved proposal for follow-up research that clearly reports within- and between-group estimands. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for group correspondence and within- or between-group change estimands must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes group correspondence and within- or between-group change estimands to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design

Related sources S01

N20 · UMIN identifier and reading of prespecified plans

Current findings: The preserved registration identifier is UMIN000052867. The UMIN number is retained in its original form, and no claim is made that the external registration has been read.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Registration identity and date, prerecruitment plans, visit hierarchy, changes, and full protocol or SAP text have not been read. Review of the existing content is incomplete.
Reason for missing information: Registration identity and date, prerecruitment plans, visit hierarchy, changes, and full protocol or SAP text have not been read.
Required materials and conditions: Actual verification scope for registration, protocol, SAP and change history
Materials to obtain first: UMIN registry history, protocol and SAP
Further research: A preserved proposal for follow-up research that links prespecified plans with the analyses actually performed. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for actual verification scope for registration, protocol, SAP and change history must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes actual verification scope for registration, protocol, SAP and change history to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Data collection and selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed; M08 Table 8.2.a, M04 §4.6.3; internal application; M04 §4.5, §4.6.3; limits of this material conversion reflect the review scope and internal design

Related sources S01

N21 · Multiple visits, sites and tests

Current findings: Positive weeks 4 and 8, the final week-12 null finding and the whole-time model are different analyses of the same trial. Multiple P values are not counted as independent replications or overall success.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. The total number of tests, site or visit selection, adjustments and prespecified analysis order are unverified. Review of the existing content is incomplete.
Reason for missing information: The total number of tests, site or visit selection, adjustments and prespecified analysis order are unverified.
Required materials and conditions: Multiplicity specification for intermediate visits, skin sites and analyses
Materials to obtain first: Multiplicity plans and complete result tables
Further research: A preserved proposal for follow-up research that distinguishes multiple-visit findings from the final primary endpoint. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for multiplicity specification for intermediate visits, skin sites and analyses must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes multiplicity specification for intermediate visits, skin sites and analyses to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort and outcome linkage is an internal application; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed

Related sources S01

N22 · Concurrent skin care, season and lifestyle

Current findings: The source scope is an identical-beverage control and 12-week follow-up. It is not supplemented with a claim that other skin care, climate, diet or lifestyle conditions were completely identical.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: The information currently needed is unverified in the preserved summary. Concurrent moisturizing or care, lifestyle, season or environment, concomitant medication and analyses of differences are unverified. Review of the existing content is incomplete.
Reason for missing information: Concurrent moisturizing or care, lifestyle, season or environment, concomitant medication and analyses of differences are unverified.
Required materials and conditions: Group-specific concurrent exposures, lifestyle, seasonal conditions and moisturizer or other care records
Materials to obtain first: Concurrent-exposure, environmental and lifestyle records and analyses
Further research: A preserved proposal for follow-up research that explicitly specifies concurrent conditions. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for group-specific concurrent exposures, lifestyle, seasonal conditions and moisturizer or other care records must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes group-specific concurrent exposures, lifestyle, seasonal conditions and moisturizer or other care records to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; own application; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptations are our own design

Related sources S01

N23 · Provision of study and placebo beverages

Current findings: The original record states that Nissin York supplied the study and placebo beverages. Product provision is not recast as absence of monetary funding or verification of an independent trial.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Provision agreements, support scope, product-quality or manufacturing records and influence on decisions are unverified. Review of the existing content is incomplete.
Reason for missing information: Provision agreements, support scope, product-quality or manufacturing records and influence on decisions are unverified.
Required materials and conditions: Manufacturer product support and scope of provision
Materials to obtain first: Product-support and provision agreements or disclosures
Further research: A proposed follow-up trial disclosing support roles; no new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for manufacturer product support and scope of provision must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes manufacturer product support and scope of provision to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S01

N24 · Employee authors and contract organization

Current findings: The manuscript's affiliations are retained: T.S., M.T. and S.S. at the Nissin York Development Research Institute, and M.M. at M&I Science. Affiliations alone do not verify all research roles or conflicts of interest.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Specific roles and independence in design, analysis, data management, writing and publication decisions are unverified. Review of the existing content is incomplete.
Reason for missing information: Specific roles and independence in design, analysis, data management, writing and publication decisions are unverified.
Required materials and conditions: Author affiliations and roles of the company and contract organization
Materials to obtain first: Author contributions, affiliations, COI and contract records
Further research: A preserved proposal for follow-up research that separately discloses company and contract-organization roles. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for author affiliations and roles of the company and contract organization must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes author affiliations and roles of the company and contract organization to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S01

N25 · Public funding, writing and publication costs

Current findings: The original summary states that separate public funding, medical-writing and publication costs were not reported. Nonreporting is not judged to establish an absence of support or all conflicts of interest.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Full original funding, medical-writing, publication-cost and other support or COI disclosures have not been read. Review of the existing content is incomplete.
Reason for missing information: Full original funding, medical-writing, publication-cost and other support or COI disclosures have not been read.
Required materials and conditions: Item-specific reporting of funding, writing and publication support
Materials to obtain first: Funding, support, medical-writing, publication-cost and COI disclosures
Further research: A preserved proposal for follow-up research that separately discloses each support category. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for item-specific reporting of funding, writing and publication support must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes item-specific reporting of funding, writing and publication support to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design

Related sources S01

N26 · Same trial and intermediate or final results

Current findings: Weeks 4, 8 and 12 in S01 Sato2025 concern one report and the same randomized-population and PPS context. Visits, skin sites, references and related sheets are not added as new independent trials or participants.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Independent replication reports under the same conditions and totals of unique trials or participants are not established. Review of the existing content is incomplete.
Reason for missing information: Independent replication reports under the same conditions and totals of unique trials or participants are not established.
Required materials and conditions: Report-to-trial, visit, site and denominator relationships and independent replication
Materials to obtain first: Cohort or protocol relationships between reports and original independent-trial reports
Further research: A preserved proposal for follow-up research that independently compares the same final and intermediate outcome specifications. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for report-to-trial, visit, site and denominator relationships and independent replication must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes report-to-trial, visit, site and denominator relationships and independent replication to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources S01

N27 · Persistence and other formulations or skin outcomes

Current findings: The manuscript records that positive findings at weeks 4 and 8 were not maintained at the final visit. These are not extended to other skin functions or diseases, general products or sustained long-term efficacy.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Other skin endpoints, follow-up beyond 12 weeks and direct comparisons in other populations or formulations are unverified. Review of the existing content is incomplete.
Reason for missing information: Other skin endpoints, follow-up beyond 12 weeks and direct comparisons in other populations or formulations are unverified.
Required materials and conditions: Distinction between intermediate changes, sustained effects and other skin or clinical outcomes
Materials to obtain first: Follow-up, other-endpoint and formulation-specific direct-trial records
Further research: A preserved proposal for follow-up research that distinguishes persistence from applicability across formulations and populations. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for distinction between intermediate changes, sustained effects and other skin or clinical outcomes must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes distinction between intermediate changes, sustained effects and other skin or clinical outcomes to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed; M03 §3.2.4; internally defined extension boundaries; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed

Related sources S01

N28 · Original safety record and scope

Current findings: The original parent safety label is Good, and the manuscript records no reported serious safety signal attributed to the study beverage over 12 weeks. This is not recast as absence of all harms or verification of safety for other products or durations.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Adverse-event types, collection and adjudication, group-specific denominators and frequencies, discontinuation, and rare or long-term harms are unverified. Review of the existing content is incomplete.
Reason for missing information: Adverse-event types, collection and adjudication, group-specific denominators and frequencies, discontinuation, and rare or long-term harms are unverified.
Required materials and conditions: 12-week safety collection, denominators and frequencies, and rare or long-term harms
Materials to obtain first: Adverse-event tables, collection methods and discontinuation or follow-up records
Further research: A preserved proposal for follow-up research that specifies harm collection and the scope of longer-term or other-population evidence. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for 12-week safety collection, denominators and frequencies, and rare or long-term harms must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes 12-week safety collection, denominators and frequencies, and rare or long-term harms to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Complements safety-data gaps for the selected subclaim. Intermediate/final skin hydration, self-reported sleepiness or parent cautionary wording are not used to judge safety or create harm-incidence estimates/new use instructions.
Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are Chamgap’s own design; M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Chamgap application

Related sources S01

N29 · Parent/subclaim, bilingual text and history

Current findings: Parent D28, B/S/R1/I0/E0/B1/C0, three false flags and blank override reasons are retained alongside the selected subclaim's grade C and note. Korean and English texts, 2026-08-26, empty correction and deliberation records, and historical cross-checking are not a current review or a subclaim score.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. Subclaim score, status and axes are absent from the source. No new score, axes or completed review are created. Review of the existing content is incomplete.
Reason for missing information: Subclaim score, status and axes are absent from the source. No new score, axes or completed review are created.
Required materials and conditions: Separate preservation of original values, axes, reference date and correction or verification statements
Materials to obtain first: Original corrections, versions and user correction comments
Further research: A preserved proposal for follow-up research that distinguishes original values and history from application of new updates. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for separate preservation of original values, axes, reference date and correction or verification statements must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes separate preservation of original values, axes, reference date and correction or verification statements to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed

Related sources S01

N30 · Summary reading, external materials and links

Current findings: The complete preserved summary and references were used for production, and source links are retained. Original articles, registration, protocol, SAP and support or COI materials have not been read or accessed. No separate external-link test was performed.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Only the relevant information in the preserved summary is recorded. Detailed source material has not been read, and review of the existing content is incomplete. The content and actual accessibility of external original articles, plans and COI materials are unverified. Review of the existing content is incomplete.
Reason for missing information: The content and actual accessibility of external original articles, plans and COI materials are unverified.
Required materials and conditions: Actual reading scope and access status of original articles, registration, plans and support records
Materials to obtain first: External original articles, registration, protocol, SAP and support records, or user input
Further research: A preserved proposal for follow-up research that distinguishes the timing and scope of acquired material when updating. No new investigation, calculation or trial was performed.
Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
Conditions for verification: Relevant source data and analysis details for actual reading scope and access status of original articles, registration, plans and support records must be provided, with unverified points identified. Preserved wording is linked here; review of the existing content is incomplete.
Why this condition is needed: This item distinguishes actual reading scope and access status of original articles, registration, plans and support records to connect the evidence needed for the selected question with the evidence currently available.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01